Draft decree for prescribing generics in Costa Rica

Home/Guidelines | Posted 09/07/2021 post-comment0 Post your comment

The decree on the 'Regulation for the Prescription of Medicines in Conformity with their International Nonproprietary Name (INN) for the Costa Rican private market' has been promoted by the Ministry of Health since 2018 and establishes that all doctors, dentists and obstetricians are obliged to prescribe medicines by their international non-proprietary name or generic name and not by brand name. The regulation also adds that doctors will be able to include the brand name of the medicine in the prescription if there are 'clinico-pharmacological reasons' that justify recommending that product.

46 MD001580

Several medical associations, health visitors, the Central American Federation of Pharmaceutical Laboratories (Fedefarma) and the Costa Rican Chamber of Health (Promed) have expressed their disagreement with the decree, likewise the Ministry insists that the decree is not ready and that it must be strengthened by completing a list of bioequivalent medicines so that they can be prescribed safely.

The Ministry of Health's database has 1,001 registered medicines in the country for consumption and distribution, but only 49 drugs have bioequivalence studies.

The Pan American Health Organisation (PAHO) has also recognized that prescribing by active ingredient (generic) could lower the price of medicines. In an interview with Radio Universidad, Gustavo Mery, advisor on health systems and services for PAHO and the World Health Organization (WHO) in Costa Rica, noted that ‘in general, it should produce a way to generate a more affordable price for me as a consumer’.

Subsequently, the obligation for doctors to justify the clinical-pharmacological reasons for prescribing by brand was removed from the decree, and the Minister of Health Daniel Salas Peraza said that this measure will only be applied in the case of medicines that do not have a therapeutic equivalent.

In August 2020, the Ministry of Health told Radio Universidad that it is working to increase the number of "bioequivalent" medicines that can be incorporated into this generic prescription modality and that this has delayed the presentation of the decree.

Editor’s comment
Readers interested to learn more about cost-minimization by generics in other countries are invited to visit www.gabi-journal.net to view the following manuscript published in GaBI Journal:

Cost-minimization analysis of generic equivalents (bortezomib, decitabine and capecitabine) in comparison to the originator brand medicines in Colombia

GaBI Journal is indexed in Embase, Scopus, Emerging Sources Citation Index and more.

Readers interested in contributing a research or perspective paper in Spanish and/or English on cost-minimization of generics to GaBI Journal – an independent, peer reviewed academic journal – please submit your manuscript here.

GaBI Journal Citation Impact
1.9 – CiteScore 2020 (calculated on 5 May 2021)
1.6 – CiteScoreTracker 2021 (Last updated on 4 June 2021)

Submit a manuscript to GaBI Journal

Related articles
Legal requirements on equivalence studies for generics in Brazil

The biosimilars market in Latin America: a summary

LATIN AMERICAN FORUM

The brand-new section the ‘Latin American Forum’ on GaBI has been launched. The objective of this new section is to provide you with all the latest news and updates on developments of generic and biosimilar medicines in Latin America in Spanish. 

View this week’s headline article: Biosimilares en Japón: una perspectiva general

Browse the news in the Latin American Forum!

Register to receive the GaBI Latin American Forum newsletter. Inform colleagues and friends of this new initiative.

LATIN AMERICAN FORUM

Se ha lanzado la nueva sección del ‘Foro Latinoamericano’ sobre GaBI. El objetivo de esta nueva sección es brindarle las últimas noticias y actualizaciones sobre desarrollos de medicamentos genéricos y biosimilares en América Latina en español.

Vea el artículo principal de esta semana: Biosimilares en Japón: una perspectiva general

Explore las noticias en el Foro Latinoamericano!

Regístrese para recibir el boletín informativo GaBI Latin American Forum. Informe a colegas y amigos sobre esta nueva iniciativa. 

  
Permission granted to reproduce for personal and non-commercial use only. All other reproduction, copy or reprinting of all or part of any ‘Content’ found on this website is strictly prohibited without the prior consent of the publisher. Contact the publisher to obtain permission before redistributing.

Copyright – Unless otherwise stated all contents of this website are © 2021 Pro Pharma Communications International. All Rights Reserved.

comment icon Comments (0)
Post your comment
Related content
FDA updates generics guidance due to COVID-19 pandemic
34 AA010660
Home/Guidelines Posted 01/10/2021
WHO guidelines on pharmaceutical pricing policies
Pay for Delay DrugsMoneyGeneric V13F21
Home/Guidelines Posted 24/09/2021
Mexico introduces new decree on health regulation
Regulation-V13H16
Home/Guidelines Posted 27/08/2021
Most viewed articles
About GaBI
Home/About GaBI Posted 05/08/2009
EU guidelines for biosimilars
EMA logo 1 V13C15
Home/Guidelines Posted 08/10/2010